Ceruloplasmin and heart failure in the atherosclerosis risk in communities study

Circulation: Heart Failure

Volumn 6, Issue 5, 2013, Pages 936-943

  Dadu, Razvan T ^a   Dodge, Rhiannon ^b,c   Nambi, Vijay ^a,b   Virani, Salim S ^a,b,d   Hoogeveen, Ron C ^a,b   Smith, Nicholas L ^h   Chen, Fengju ^c   Pankow, James S ^e   Guild, Cameron ^f   Tang, W H Wilson ^g   Boerwinkle, Eric ^c   Hazen, Stanley L ^g   Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiovascular diseases; Ceruloplasmin; Heart failure; Polymorphism single nucleotide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CERULOPLASMIN; TROPONIN T;

ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CERULOPLASMIN BLOOD LEVEL; CHROMOSOME 3; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HEART FAILURE; HETEROZYGOTE; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; CERULOPLASMIN; HEART FAILURE; POLYMORPHISM, SINGLE NUCLEOTIDE;

AFRICAN AMERICANS; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CERULOPLASMIN; CHROMOSOMES, HUMAN, PAIR 3; DISEASE-FREE SURVIVAL; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEART FAILURE; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84887484633     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000270     Document Type: Article

References (29)

1. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, Miyajima H, Hogg N, Harris ZL, Gladwin MT. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol. 2006;2:486-493.
2. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis. 2006;187:238-250.
3. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388-398.
4. Michel T. NO way to relax: the complexities of coupling nitric oxide synthase pathways in the heart. Circulation. 2010;121:484-486.
5. Tang WH, Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, McPherson R, Fox PL, Allayee H, Hazen SL. Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32:516-522.
6. Kim OY, Shin MJ, Moon J, Chung JH. Plasma ceruloplasmin as a biomarker for obesity: a proteomic approach. Clin Biochem. 2011; 44:351-356.
7. Göçmen AY, Sahin E, Semiz E, Gümuşlü S. Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease? Can J Cardiol. 2008;24:209-212.
8. Klipstein-Grobusch K, Grobbee DE, Koster JF, Lindemans J, Boeing H, Hofman A, Witteman JC. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr. 1999;81:139-144.
9. Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis. 2008;26:196-202.
10. Brunetti ND, Correale M, Pellegrino PL, Cuculo A, Biase MD. Acute phase proteins in patients with acute coronary syndrome: correlations with diagnosis, clinical features, and angiographic findings. Eur J Intern Med. 2007;18:109-117.
11. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002;105:2632-2637.
12. Engström G, Hedblad B, Tydén P, Lindgärde F. Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis. 2009;202:617-622.
13. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
14. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339:861-867.
15. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
16. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J. 2007;28:1374-1381.
17. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) Study. J Am Coll Cardiol. 2009;54:2388-2395.
18. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle- aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004;109:837-842.
19. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367-1376.
20. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, Cupples LA, Dehghan A, Lumley T, Rosamond WD, Lieb W, Rivadeneira F, Bis JC, Folsom AR, Benjamin E, Aulchenko YS, Haritunians T, Couper D, Murabito J, Wang YA, Stricker BH, Gottdiener JS, Chang PP, Wang TJ, Rice KM, Hofman A, Heckbert SR, Fox ER, O'Donnell CJ, Uitterlinden AG, Rotter JI, Willerson JT, Levy D, van Duijn CM, Psaty BM, Witteman JC, Boerwinkle E, Vasan RS. Association of genomewide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256-266.
21. Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003;19:149-150.
22. Reunanen A, Knekt P, Aaran RK. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol. 1992;136:1082-1090.
23. Arredondo M, Núñez H, López G, Pizarro F, Ayala M, Araya M. Influence of estrogens on copper indicators: in vivo and in vitro studies. Biol Trace Elem Res. 2010;134:252-264.
24. Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. Am J Clin Nutr. 1992;56:917-925.
25. Frieden E, Hsieh HS. The biological role of ceruloplasmin and its oxidase activity. Adv Exp Med Biol. 1976;74:505-529.
26. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
27. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation. 1997;96:2414-2420.
28. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97:1536-1539.
29. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181-H2190.